Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Pharmacodynamic Drug-Drug Interactions.

Niu J, Straubinger RM, Mager DE.

Clin Pharmacol Ther. 2019 Jun;105(6):1395-1406. doi: 10.1002/cpt.1434. Epub 2019 Apr 26.

PMID:
30912119
2.

Rituximab dosing in hematological malignancies: an old question, revisited.

Morcos PN, Boehnke A, Valente N, Mager DE.

Cancer Chemother Pharmacol. 2019 Sep;84(3):661-666. doi: 10.1007/s00280-019-03818-1. Epub 2019 Mar 21.

PMID:
30899984
3.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD; AIDS Clinical Trials Group Study A5202 Team.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01638-18. doi: 10.1128/AAC.01638-18. Print 2019 Apr.

PMID:
30642925
4.

Machine Learning Models for the Prediction of Chemotherapy-Induced Peripheral Neuropathy.

Bloomingdale P, Mager DE.

Pharm Res. 2019 Jan 7;36(2):35. doi: 10.1007/s11095-018-2562-7.

PMID:
30617559
5.

Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma.

Ramakrishnan V, Mager DE.

CPT Pharmacometrics Syst Pharmacol. 2019 Mar;8(3):146-157. doi: 10.1002/psp4.12358. Epub 2018 Dec 4.

6.

Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects on Bone Homeostasis in Multiple Myeloma Patients.

Zhang L, Mager DE.

J Pharm Sci. 2019 Jan;108(1):732-740. doi: 10.1016/j.xphs.2018.11.024. Epub 2018 Nov 22.

PMID:
30472266
7.

Fifty-Eight Years and Counting: High-Impact Publishing in Computational Pharmaceutical Sciences and Mechanism-Based Modeling.

Amidon GE, Anderson BD, Balthasar JP, Bergstrom CAS, Huang SM, Kasting G, Kesisoglou F, Khinast JG, Mager DE, Roberts CJ, Yu L.

J Pharm Sci. 2019 Jan;108(1):2-7. doi: 10.1016/j.xphs.2018.11.002. Epub 2018 Nov 10.

PMID:
30423338
8.

The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients.

Campagne O, Mager DE, Brazeau D, Venuto RC, Tornatore KM.

Br J Clin Pharmacol. 2019 Mar;85(3):516-529. doi: 10.1111/bcp.13811. Epub 2019 Jan 4.

PMID:
30414331
9.

Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?

Campagne O, Mager DE, Tornatore KM.

J Clin Pharmacol. 2019 Mar;59(3):309-325. doi: 10.1002/jcph.1325. Epub 2018 Oct 29. Review.

PMID:
30371942
10.

Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients.

Campagne O, Mager DE, Brazeau D, Venuto RC, Tornatore KM.

J Clin Pharmacol. 2018 Sep;58(9):1184-1195. doi: 10.1002/jcph.1118. Epub 2018 May 18.

11.

Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.

Ramakrishnan V, Mager DE.

J Pharmacol Exp Ther. 2018 Jun;365(3):734-751. doi: 10.1124/jpet.118.247924. Epub 2018 Apr 9.

12.

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity.

Campagne O, Delmas A, Fouliard S, Chenel M, Chichili GR, Li H, Alderson R, Scherrmann JM, Mager DE.

Clin Cancer Res. 2018 Jun 1;24(11):2631-2641. doi: 10.1158/1078-0432.CCR-17-2265. Epub 2018 Feb 20.

13.

Quantitative systems toxicology.

Bloomingdale P, Housand C, Apgar JF, Millard BL, Mager DE, Burke JM, Shah DK.

Curr Opin Toxicol. 2017 Jun;4:79-87. doi: 10.1016/j.cotox.2017.07.003. Epub 2017 Aug 2.

14.

Boolean network modeling in systems pharmacology.

Bloomingdale P, Nguyen VA, Niu J, Mager DE.

J Pharmacokinet Pharmacodyn. 2018 Feb;45(1):159-180. doi: 10.1007/s10928-017-9567-4. Epub 2018 Jan 6.

15.

Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts.

Nanavati C, Ruszaj D, Mager DE.

CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):756-764. doi: 10.1002/psp4.12246. Epub 2017 Oct 17.

16.

A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates.

Ait-Oudhia S, Zhang W, Mager DE.

AAPS J. 2017 Sep;19(5):1436-1448. doi: 10.1208/s12248-017-0113-5. Epub 2017 Jun 23.

PMID:
28646408
17.

Influence of Meals and Glycemic Changes on QT Interval Dynamics.

Cirincione B, Sager PT, Mager DE.

J Clin Pharmacol. 2017 Aug;57(8):966-976. doi: 10.1002/jcph.933. Epub 2017 May 22.

18.

Model-Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion.

Cirincione B, LaCreta F, Sager P, Mager DE.

J Clin Pharmacol. 2017 Aug;57(8):956-965. doi: 10.1002/jcph.882. Epub 2017 May 22.

19.

Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells.

Nanavati C, Mager DE.

Pharm Res. 2017 Mar;34(3):668-679. doi: 10.1007/s11095-017-2095-5. Epub 2017 Jan 18.

20.

Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.

Cirincione B, Edwards J, Mager DE.

AAPS J. 2017 Mar;19(2):487-496. doi: 10.1208/s12248-016-9975-1. Epub 2016 Nov 28.

PMID:
27896683
21.

Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.

Ait-Oudhia S, Ovacik MA, Mager DE.

MAbs. 2017 Jan;9(1):15-28. doi: 10.1080/19420862.2016.1238995. Epub 2016 Sep 23. Review.

22.

Array of translational systems pharmacodynamic models of anti-cancer drugs.

Ait-Oudhia S, Mager DE.

J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):549-565. Epub 2016 Oct 22. Review.

PMID:
27771815
23.

Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice.

Jiang XL, Shen HW, Mager DE, Schmidt S, Yu AM.

Acta Pharm Sin B. 2016 Sep;6(5):492-503. Epub 2016 Aug 6.

24.

Population pharmacokinetics of exenatide.

Cirincione B, Mager DE.

Br J Clin Pharmacol. 2017 Mar;83(3):517-526. doi: 10.1111/bcp.13135. Epub 2016 Nov 16.

25.

Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV.

Biopharm Drug Dispos. 2016 Oct;37(7):409-420. doi: 10.1002/bdd.2023. Epub 2016 Sep 13.

26.

Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.

Ait-Oudhia S, Mager DE, Pokuri V, Tomaszewski G, Groman A, Zagst P, Fetterly G, Iyer R.

CPT Pharmacometrics Syst Pharmacol. 2016 Jun;5(6):297-304. doi: 10.1002/psp4.12084. Epub 2016 Jun 8.

27.

A Six-Stage Workflow for Robust Application of Systems Pharmacology.

Gadkar K, Kirouac DC, Mager DE, van der Graaf PH, Ramanujan S.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):235-49. doi: 10.1002/psp4.12071. Epub 2016 Apr 16.

28.

Calculated Log D Is Inversely Correlated With Select Camptothecin Clearance and Efficacy in Colon Cancer Xenografts.

Nanavati C, Mager DE.

J Pharm Sci. 2016 Apr;105(4):1561-6. doi: 10.1016/j.xphs.2016.01.026.

29.

Physiologically-Based Pharmacokinetic-Pharmacodynamic Modeling of 1α,25-Dihydroxyvitamin D3 in Mice.

Ramakrishnan V, Yang QJ, Quach HP, Cao Y, Chow EC, Mager DE, Pang KS.

Drug Metab Dispos. 2016 Feb;44(2):189-208. doi: 10.1124/dmd.115.067033. Epub 2015 Nov 19.

PMID:
26586377
30.

Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.

Zhang L, Mager DE.

J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):541-52. doi: 10.1007/s10928-015-9445-x. Epub 2015 Sep 21.

31.

The American Conference on Pharmacometrics 2015 (ACoP6).

Jin JY, Mager DE.

J Pharmacokinet Pharmacodyn. 2015 Oct;42 Suppl 1:1-2. doi: 10.1007/s10928-015-9431-3. No abstract available.

PMID:
26370673
32.

Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.

Chudasama VL, Ovacik MA, Abernethy DR, Mager DE.

J Pharmacol Exp Ther. 2015 Sep;354(3):448-58. doi: 10.1124/jpet.115.224766. Epub 2015 Jul 10.

33.

Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.

McCune JS, Mager DE, Bemer MJ, Sandmaier BM, Storer BE, Heimfeld S.

Cancer Chemother Pharmacol. 2015 Jul;76(1):85-96. doi: 10.1007/s00280-015-2768-x. Epub 2015 May 17.

34.

PKPD modelling to predict altered disposition of 1α,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation.

Quach HP, Yang QJ, Chow EC, Mager DE, Hoi SY, Pang KS.

Br J Pharmacol. 2015 Jul;172(14):3611-26. doi: 10.1111/bph.13153. Epub 2015 May 15.

35.

Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies.

Chudasama VL, Zutshi A, Singh P, Abraham AK, Mager DE, Harrold JM.

J Pharmacokinet Pharmacodyn. 2015 Feb;42(1):1-18. doi: 10.1007/s10928-014-9401-1. Epub 2015 Jan 6.

PMID:
25559227
36.

Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration.

Fathallah AM, Turner MR, Mager DE, Balu-Iyer SV.

Biopharm Drug Dispos. 2015 Mar;36(2):115-25. doi: 10.1002/bdd.1925. Epub 2014 Dec 20.

37.

Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

McCune JS, Vicini P, Salinger DH, O'Donnell PV, Sandmaier BM, Anasetti C, Mager DE.

Cancer Chemother Pharmacol. 2015 Jan;75(1):67-75. doi: 10.1007/s00280-014-2618-2. Epub 2014 Nov 6.

38.

Mathematical model of platelet turnover in thrombocytopenic and nonthrombocytopenic preterm neonates.

Kulshrestha M, Sola-Visner M, Widness JA, Veng-Pedersen P, Mager DE.

Am J Physiol Heart Circ Physiol. 2015 Jan 1;308(1):H68-73. doi: 10.1152/ajpheart.00528.2013. Epub 2014 Oct 31.

39.

Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats.

Kagan L, Zhao J, Mager DE.

Pharm Res. 2014 Dec;31(12):3265-73. doi: 10.1007/s11095-014-1416-1. Epub 2014 May 23.

40.

The ISoP Standards and Best Practices Committee.

Bruno R, Mentré F, Tannenbaum S, Wang Y, Corrigan B, Mager DE.

Clin Pharmacol Ther. 2014 Jun;95(6):581-2. doi: 10.1038/clpt.2014.65.

PMID:
24842638
41.

Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.

Li H, Mager DE, Sandmaier BM, Storer BE, Boeckh MJ, Bemer MJ, Phillips BR, Risler LJ, McCune JS.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1121-9. doi: 10.1016/j.bbmt.2014.03.032. Epub 2014 Apr 13.

42.

Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.

Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV.

J Pharm Sci. 2015 Feb;104(2):388-95. doi: 10.1002/jps.23963. Epub 2014 Apr 2.

43.

Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.

Ait-Oudhia S, Mager DE, Straubinger RM.

Pharmaceutics. 2014 Mar 18;6(1):137-74. doi: 10.3390/pharmaceutics6010137.

44.

Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan.

Liu ZJ, Hoffmeister KM, Hu Z, Mager DE, Ait-Oudhia S, Debrincat MA, Pleines I, Josefsson EC, Kile BT, Italiano J Jr, Ramsey H, Grozovsky R, Veng-Pedersen P, Chavda C, Sola-Visner M.

Blood. 2014 May 29;123(22):3381-9. doi: 10.1182/blood-2013-06-508200. Epub 2014 Mar 5.

45.

Mechanistic vs. Empirical network models of drug action.

Birtwistle MR, Mager DE, Gallo JM.

CPT Pharmacometrics Syst Pharmacol. 2013 Sep 6;2:e72. doi: 10.1038/psp.2013.51.

46.

Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.

Kosloski MP, Pisal DS, Mager DE, Balu-Iyer SV.

Biopharm Drug Dispos. 2014 Apr;35(3):154-63. doi: 10.1002/bdd.1880. Epub 2014 Jan 2.

47.

Population-based meta-analysis of furosemide pharmacokinetics.

Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE.

Biopharm Drug Dispos. 2014 Mar;35(2):119-33. doi: 10.1002/bdd.1874. Epub 2013 Nov 16.

PMID:
24151207
48.

Population-based meta-analysis of hydrochlorothiazide pharmacokinetics.

Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE.

Biopharm Drug Dispos. 2013 Dec;34(9):527-39. doi: 10.1002/bdd.1863. Epub 2013 Oct 10.

PMID:
24123104
49.

Network-based approaches in drug discovery and early development.

Harrold JM, Ramanathan M, Mager DE.

Clin Pharmacol Ther. 2013 Dec;94(6):651-8. doi: 10.1038/clpt.2013.176. Epub 2013 Sep 11. Review.

50.

Population pharmacodynamic modeling of hyperglycemic clamp and meal tolerance tests in patients with type 2 diabetes mellitus.

Hong Y, Dingemanse J, Sidharta P, Mager DE.

AAPS J. 2013 Oct;15(4):1051-63. doi: 10.1208/s12248-013-9512-4. Epub 2013 Aug 1.

Supplemental Content

Loading ...
Support Center